Impaired Tissue Oxygen Delivery in Patients With Coexistent COPD-heart Failure: What Consequences on Neuromuscular Fatigue During Exercise?

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Rationale. Chronic obstructive pulmonary disease (COPD) and heart failure (HF) coexist in approximately one third of patients presenting with one of these conditions. From a clinical standpoint, impaired tissue oxygen (O2) delivery stands as a common pathological mechanism of these cardiorespiratory diseases. Recent evidence suggest that muscle and cerebral blood flow and oxygenation are further impaired during exercise in patients with COPD-HF overlap compared to isolated diseases. However, it remains unknown whether impaired O2 delivery is associated with exaggerated manifestations of peripheral and central fatigue in COPD-HF overlap. In addition, improving cardiopulmonary interactions through non invasive positive pressure ventilation or through the addition of a hyperoxic gas mixture during exercise have been associated with enhanced cerebral and muscle O2 delivery and oxygenation in patients with COPD or HF. It is, therefore, conceivable that improved O2 delivery to these structures have beneficial influence on exercise capacity in patients with COPD-HF overlap due to less peripheral and central fatigue. Aims. To investigate the influence of impaired O2 delivery during exercise, and its alleviation with different interventions (non invasive positive pressure ventilation or hyperoxia), on neuromuscular fatigue in patients with COPD-HF.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years;

• COPD: mild-to-severe airflow obstruction (forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio \<0.70; post-bronchodilator FEV1 \> 30% predicted);

• HF: reduced left ventricular ejection fraction (\<50%, for COPD-HF patients only);

• HF: New York Heart Association Functional Classification I to III (for COPD-HF patients only);

• Clinical stability for both diseases (COPD and/or HF) and no recent (within 3 months) exacerbation requiring a change in medications;

• Patient benefiting from health care coverage;

• Patient able to provide written informed consent.

Locations
Other Locations
France
CHU Grenoble Alpes - Hopital Sud (Laboratoire HP2)
RECRUITING
Échirolles
Contact Information
Primary
Stéphane Doutreleau, MD, PhD
sdoutreleau@chu-grenoble.fr
+33476767773
Backup
Mathieu Marillier, PhD
mmarillier@chu-grenoble.fr
+33681552231
Time Frame
Start Date: 2023-02-21
Estimated Completion Date: 2025-12
Participants
Target number of participants: 40
Treatments
Active_comparator: Patients with COPD
Patients with COPD will only exercise under medical air (for between-group comparison: COPD vs COPD-HF)
Experimental: Patients with COPD-HF overlap
Patients with COPD-HF overlap will first exercise under medical air (for between-group comparison: COPD vs COPD-HF); Patients with COPD-HF overlap will then exercise under intervention (hyperoxia, for within-group comparison: medical air vs intervention trial)
Sponsors
Leads: University Hospital, Grenoble

This content was sourced from clinicaltrials.gov